Abstract：OBJECTIVE To use IFNα injection as inhalant for there is no proper dosage form for aerosol inhalation and evaluate the feasibility of IFN-α off-label use. METHODS The clinical studies in SARS and MERS were reviewed to discuss the efficacy and safety of IFN-α application in COVID-19. Meanwhile, the features of aerosol inhalation, characteristics of IFN-α and related clinical researches were analyzed to argue the possibility of IFN-α aerosol inhalation. RESULTS IFN-α seems to be effective in relieving early symptoms but likely invalid in reducing mortality of severe patients, however, the exact therapeutic effect calls for further clinical tests. Proper atomization of IFN-α injection won't reduce biological activity of the protein, but absorption and utilization of IFN-α in lung may be unsatisfactory for the lack of sorbefacient. More than that, ingredients in IFN-α injection may increase risk of adverse reaction. CONCLUSION The aerosol inhalation of IFN-α injection should be fully evaluated on the side of patients. If there is a lack of proper atomization device or operation staff, subcutaneous injection of IFN-α may be a tentative administration.
ZHANG X. Effect of recombinant human interferon in the treatment of pneumonia [J]. Chin Foreign Med Res (中外医学研究),2015,13(36):21-22.
[2]
MORGENSTERN B, MICHAELIS M, BAER P C, et al. Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines [J]. Biochem Biophys Res Commun, 2005, 326 (4):905-908.
[3]
HAAGMANS B L, KUIKEN T, MARTINA B E, et al. Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques [J]. Nat Med, 2004, 10 (3):290-293.
[4]
CHRISTIAN M D, POUTANEN S M, LOUTFY M R, et al. Severe acute respiratory syndrome [J]. Clin Infect Dis, 2004, 38: 1420-1427.
[5]
LOUTFY M R, BLATT L M, SIMINOVITCH K A, et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study [J]. JAMA, 2003, 290 (24):3222-3228.
[6]
ZHAO Z. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China [J]. J Med Microbiol, 2003, 52 (8):715-720.
[7]
STOCKMAN L J, BELLAMY R, GARNER P. SARS: systematic review of treatment effects [J].PLoS Med, 2006, 3(9):e343.
[8]
CHAN R W, CHAN M C, AGNIHOTHRAM S, et al. Tropism of and innate immune responses to the novel human betacoronavirus lineage C virus in human ex vivo respiratory organ cultures [J]. J Virol, 2013, 87 (12):6604-6614.
[9]
FALZARANO D, DE WIT E, RASMUSSEN A L, et al. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques[J]. Nat Med, 2013, 19 (10):1313-1317.
[10]
HABIB A M, ALIM A E, ZOUAOUI B R, et al. Clinical outcomes among hospital patients with Middle East respiratory syndrome coronavirus (MERS-CoV) infection[J]. BMC Infect Dis, 2019,19(1):870-875.
[11]
AL GHAMDI M, ALGHAMDI K M, GHANDOORA Y, et al. Treatment outcomes for patients with Middle Eastern Respiratory Syndrome Coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia [J]. BMC Infect Dis, 2016, 16 (1):174-180.
[12]
SARAH S, FAYSSAL F, ABDULLAH A J, et al. IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study [J]. J Antimicrob Chemother, 2015, 70(7):2129-2132.
[13]
OMRANI A S, SAAD M M, BAIG K, et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study[J]. Lancet Infect Dis, 2014, 14 (11):1090-1095.
[14]
ARABI Y M, BALKHY H, AL-OMARI A, et al. Ribavirin and interferon for critically Ill patients with Middle East Respiratory Coronavirus (MERS-CoV) infection[C]// American Thoracic Society May 15-20, 2015.
[15]
CHEN M, TONG R S, BIAN Y, et al. Evidence-based rapid review on possibility of treatment of 2019-nCoV with subcutaneous α-interferon[J]. Her Med(医药导报):http://kns.cnki.net/kcms/detail/42.1293.R.20200210.1759.002.html.
[16]
HAN F, HUANG X, ZHAO Z D, et al. Current situation and analysis on nebulized inhalation: preparation of pulmonary drug delivery system [J]. China J Tradit Chin Med Pharm(中华中医药杂志), 2014,29(7):2084-2088.
[17]
TANG Y,DU G. Clinical application status and medication mismanagement of atomization inhalation therapy in China [J]. Her Med (医药导报), 2019,38(12):1557-1561.
[18]
COMPILATION TEAM OF "EXPERT CONSENSUS ON RATIONAL USE OF AEROSOL INHALATION THERAPY" ,CLINICAL PHARMACY BRANCH OF CHINESE MEDICAL ASSOCIATION. Expert consensus on rational medication of aerosol therapy (2019 edition) [J]. Her Med(医药导报), 2019, 38(2):135-146.
[19]
MA H J, HUANG Q R, JIANG X G, et al. Analysis of biological activity, particle size and safety after atomization inhalation of recombinant human interferon-α1b [J]. Electronic J Clin Med Literature(临床医药文献电子杂志), 2019, 6 (33):812.
[20]
JIANG R G. Design and evaluation of recombinant human interferon α-2b dry powder inhaler [D]. Shenyang: University of Shenyang Pharmaceutical, 2005.
[21]
CHATELUT E, ROSTAING L, GREGOIRE N, et al. A pharmacokinetic model for alpha interferon administered subcutaneously [J]. Br J Clin Pharmacol, 1999, 47 (4):365-371.
[22]
YEH M K, COOMBES A G, JENKINS P, et al. Polymer microparticles for drug delivery: WO 9535097[P]. 19991228.
[23]
PATTON J S, TRINCHERO P, PLATZ R M. Bioavailability of pulmonary delivered peptides and proteins: α-interferon, calcitonins and parathyroid homrones [J]. J Controlled Release, 1994, 28 (1-3):79-85.
[24]
O'RIORDAN T G. Formulations and nebulizer performance[J]. Respir Care, 2002, 47(11):1305-1312; discussion 1312-1313.
[25]
WYDE P R, WILSON S Z, KRAMER M J, et al. Pulmonary deposition and clearance of aerosolized interferon [J]. Antimicrob Agents Ch, 1984, 25 (6):729-734.
[26]
IPA Y, ARKAWAA T, SILVERS H, et al. Stability of recombinant consensus interferon to air-jet and ultrasonic nebulization [J]. J Pharm Sci, 1995, 84 (10):1210-1214.
[27]
WANG B, CHENG T, LU C, et al. The effects of atomization inhalation on biological activity and molecular structure of human recombinant interferon alpha 2b [J]. J Pediatr Pharm(儿科药学杂志), 2017,23(3):59.
[28]
DAI J X, YOU C H, QI Z T, et al. Children's respiratory viral diseases treated with interferon aerosol [J]. Chin Med J(中华医学杂志:英文版), 1987, 100(2):162-166.
[29]
THIPPHAWONG J. Inhaled cytokines and cytokine antagonists [J]. Adv Drug Deliver Rev, 2006, 58 (9-10):1089-1105.
[30]
SHEN K L, ZHANG G C, SHANG Y, et al. Expert consensus on clinical application of recombinant human interferon-α1b in pediatrics [J]. Chin J Appl Clin Pediatr (中华实用儿科临床杂志), 2015, 30 (16):1214-1219.
[31]
LIU J F, LIU J J, CHU L P, et al. Biodistribution and metabolic pathway of interferon-α1b administered by aerosol inhalation in rabbits [J]. Her Med(医药导报), 2013, 32 (1):15.
[32]
ZHANG G C, SHANG X Y. Interpretation on specialists consensus on pediatric clinical application of recombinant human interferon-α1b[J]. Chin J Appl Clin Pediatr (中华实用儿科临床杂志), 2015, 30 (16):1220-1222.
[33]
GIOSUE S, CASARINI S, AMEGLIO F, et al. Minimal dose of aerosolized interferon-α in human subjects: biological consequences and side-effects [J]. Eur Respir J, 1996, 9(1):42-46.
[34]
BALWANI G, BOYD B, WHATLEY J, et al. Evaluation of the AERx® system for the pulmonary delivery of recombinant human interferon ALFA-2b to healthy subjects [C]. 29th Annual Meeting of the Controlled Release Society, Seoul, South Korea, 2002.
[35]
RAO R D, MARKOVIC S N, ANDERSON P M. Aerosol therapy for malignancy involving the lungs [J]. Curr Cancer Drug Targets, 2003,3(4):239-250.
[36]
MAASILTA P, HALME M, MATTSON K, et al. Pharmacokinetics of inhaled recombinant and natural alpha interferon [J]. Lancet, 1991, 337(8737): 371.
[37]
KINNULA V, MATTSON K, CANTELL K. Pharmacokinetics and toxicity of inhaled human interferon-alpha in patients with lung cancer [J]. J Interf Res, 1989, 9(4): 419-423.
[38]
ZANDWIJK N V, JASSEM E, DUBBELMANN R, et al. Aerosol application of interferon-alpha in the treatment of bronchioloalveolar carcinoma [J]. Eur J Cancer, 1990, 26(6): 738-740.
[39]
KINNULA V, CANTELL K, MATTSON K. Effect of inhaled natural interferon-alpha on diffuse bronchioalveolar carcinoma [J]. Eur J Cancer, 1990, 26(6): 740-741.
[40]
MAASILTA P, HOLSTI L R, HALME M, et al. Natural alpha-interferon in combination with hyperfractionated radiotherapy in the treatment of non-small cell lung cancer [J]. Int J Radiat Oncol Biol Phys, 1992, 23(4):863-868.
[41]
GIOSUE S, CASARINI M, ALEMANNO L, et al.Effects of aerosolized interferon-α in patients with pulmonary tuberculosis [J]. Am J Respir Crit Care Med, 1998, 158(4): 1156-1162.
[42]
GIOSUE S, CASARINI M, ALEMANNO L, et al. Aerosolized interferon-alpha treatment in patients with multi-drug resistant pulmonary tuberculosis [J]. Eur Cytokine Netw, 2000, 11(1): 99-104.
[43]
KRASNOWSKA M, MAŁOLEPSZY J, LIEBHART E, et al. Inhaled natural human interferon alpha induces bronchospastic reactions in asthmatics [J]. Arch Immunol Ther Exp, 1992, 40(1): 75-78.
[44]
ZHAO R S, YANG Y H, YANG L, et al. Coronavirus SARS-CoV-2 infection: expert consensus on guidance and prevention and control strategies for hospital pharmaceutical work [J]. Chin Pharm J(中国药学杂志), 2020, 55 (4):268-277.
[45]
MAO Q G, TANG J M, CAI B C, et al. Observation on the curative effect of two interferon-α administrations in the treatments of chronic hepatitis B [J]. China Med(中国医药), 2007, 2(3):167-169.
2020, Vol. 55 
